Top Markets
#1 Derive Derive +28.10%
#2 MowCat MowCat +25.96%
#3 Geodnet Geodnet +22.61%
#4 Cross Cross +15.32%
#5 Humanity Humanity +12.43%
#6 aPriori aPriori +10.37%
#7 Biconomy Biconomy +9.73%
#8 The Bitcoin Bull The Bitcoin Bull +8.51%
#9 Cap Cap +8.46%
#10 Velvet Velvet +8.39%
Coin of the day
Derive Derive
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Classifica tra le azioni #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Prezzo delle azioni
$1.84
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$3.51M
Variazione (1 giorno)
0.46%
Variazione (1 anno)
-62.71%
Paese
US
Scambia Dogwood Therapeutics, Inc. (DWTX)

Categoria

Healthcare
Utile per Dogwood Therapeutics, Inc. (DWTX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Dogwood Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Dogwood Therapeutics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE